Alaunos and Scinai Stocks Rally on Acquisition and New Manufacturing Deals

Key Facts

1Alaunos Therapeutics stock surged 200% following the acquisition of Velaris and a $350 million capital raise.

2Scinai Immunotherapeutics shares jumped 27% after securing a $5.1 million biopharma manufacturing deal.

Alaunos Therapeutics stock surged 200% following the acquisition of Velaris and a $350 million capital raise. Benzinga reported that the funding is intended to support PAH therapies through 2029. Simultaneously, Scinai Immunotherapeutics shares jumped 27% after the company secured a $5.1 million biopharma manufacturing deal.

TCRT closed at $1.05 on October 12, 2026, reaching a day high of $1.05 during the session. On the same date, SCNI closed at $1.16, with the stock trading between a low of $1.11 and a high of $1.2. These significant price movements follow major corporate actions including strategic acquisitions and new revenue-generating manufacturing contracts.